Review articles cover how pre-MEASURE has impacted clinical decision-making and the interpretation of NPM1 MRD throughout the treatment course of AML. Other manuscripts address the limitations of ...

The company recently announced that its pivotal Phase 2 KOMET-001 trial in relapsed/refractory NPM1-mutated AML met ... and minimal residual disease (MRD) negativity in challenging AML frontline ...

Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, Inc., financial results conference call. (Operator Instructions) Please note this call is being recorded. It is now my pleasure to ...

Kura Oncology Inc (KURA) reports significant revenue growth and strategic progress in its Q4 2024 earnings call, setting the ...

Net loss for the fourth quarter of 2024 was $19.2 million, compared to a net loss of $42.8 million for the fourth quarter of 2023. Net loss for the full year 2024 was $174.0 million, compared to a net ...